HK Stock Market Move | HANXBIO-B(03378) rose nearly 9% in the closing session. The company will present four poster research findings at the AACR annual conference.

HANXBIO-B (03378) rose nearly 9% at the close, up 8.65% as of press time, at HK$31.92, with a turnover of HK$3.0669 million. On the news front, the American Association for Cancer Research (AACR) Annual Meeting will be held in San Diego, USA from April 17-22. HANSIGHT previously announced that the company's four innovative drug research results will be presented in poster form at the 2026 AACR Annual Meeting. The selected results further validate the company's research and development capabilities and innovation. Among them is the presentation of the HX044 poster. HX044 is a global innovative CTLA-4/SIRP dual fusion protein, the next generation of CTLA-4 targeted therapy, which enhances the removal of regulatory T-cells in the tumor microenvironment by simultaneously targeting CTLA-4 and CD47, reducing immune suppression of tumors, enhancing anti-tumor activity. The main development direction is PD-1/ICI-resistant solid tumors, forming a complementary tumor immunotherapy pipeline layout with the company's research of HX009.